Live Analyst Rating Changes 41205 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kumaraguru Raja
BROO

Kumaraguru Raja

Brookline Capital Markets
Wall Street Analyst
★☆☆☆☆
#3191
on 13Foresight · ranked by our own returns
34%
Success Rate
-1.2%
Average Return
11 of 32 calls profitable · -30.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 34% of Kumaraguru Raja's ratings turned a profit when each position was held for 2 year — averaging -1.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

4 Buy 1 Hold 0 Sell
Kumaraguru's Stock Coverage 49 ratings · 2026-10-13
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
BMEA
Biomea Fusion
 Oct 07, 2026 BUY Strong Buy
+871.9% avg upside
16 analysts
$10.00
621.95% Upside
 +0.0% ·
EDSA
Edesa Biotech
 Jun 29, 2026 BUY Strong Buy
+273.6% avg upside
6 analysts
$21.00
564.61% Upside
 -62.8% ·
ERNA
Eterna Therapeutics
 May 07, 2026 BUY Strong Buy
+2938.2% avg upside
4 analysts
$30.00
1239.21% Upside
 -69.3% ·
IRD
Opus Genetics
 Dec 01, 2025 BUY Strong Buy
+166.3% avg upside
25 analysts
$8.00
72.08% Upside
 +132.5% ·
MDCX
Medicus Pharma Ltd
 Sep 24, 2025 BUY Strong Buy
+1936.2% avg upside
6 analysts
$20.00
440.59% Upside
 +28.6% ·
NBP
NovaBridge Biosciences
 Aug 28, 2025 BUY Strong Buy
+1503.1% avg upside
14 analysts
$8.00
506.08% Upside
 -67.2% ·
INTS
Intensity Therapeutics, Inc.
 Aug 12, 2025 BUY Strong Buy
+1080.5% avg upside
6 analysts
$75.00
2288.55% Upside
 -50.6% ·
ADIL
Adial Pharmaceuticals
 Jun 26, 2025 BUY Strong Buy
+1189.4% avg upside
7 analysts
$50.00
1269.90% Upside
 -66.8% ·
HURA
TuHURA Biosciences
 Jun 23, 2025 BUY Strong Buy
+386.8% avg upside
8 analysts
$9.00
361.52% Upside
 -22.5% ·
MNPR
Monopar Therapeutics Inc
 May 13, 2025 BUY Strong Buy
+38.6% avg upside
18 analysts
$58.00
24.91% Downside
 +133.5% ·
IRLA
IRulya Therapeutics
 Dec 18, 2024 BUY Buy
+450.4% avg upside
19 analysts
$9.00
69.81% Downside
 · ·
PALI
Palisade Bio
 Nov 20, 2024 BUY Strong Buy
+1533.3% avg upside
16 analysts
$38.00
2282.52% Upside
 -39.8% ·
OSTX
OS Therapies Incorporated
 Aug 22, 2024 BUY Strong Buy
+622.3% avg upside
5 analysts
$9.00
471.48% Upside
 -60.5% ·
UNCY
Unicycive Therapeutics
 Jul 09, 2024 BUY Strong Buy
+1217.1% avg upside
10 analysts
$80.00
1905.04% Upside
 +10.5% ·
SABS
SAB Biotherapeutics
 Jun 06, 2024 BUY Strong Buy
+280.7% avg upside
14 analysts
$8.00
177.69% Upside
 +19.0% ·
GNTA
Genenta Science SpA Sponsored ADR
 Jun 29, 2023 BUY Strong Buy
+1986.4% avg upside
3 analysts
$15.00
1924.20% Upside
 -47.5% ·
ATYR
aTyr Pharma
 Mar 03, 2023 BUY Buy
+3706.5% avg upside
17 analysts
$9.00
3968.70% Upside
 +51.0% ·
DARE
Daré Bioscience
 Jan 05, 2023 BUY Strong Buy
+1693.2% avg upside
14 analysts
$5.00
566.81% Upside
 -71.5% ·
NMTRQ
9 Meters Biopharma
 Nov 29, 2022 BUY Buy
+3234374900.0% avg upside
11 analysts
$74.00
7399999900.09% Upside
 · ·
BIOCQ
Biocept
 Oct 17, 2022 BUY Strong Buy
+8407499900.0% avg upside
7 analysts
$330.00
32999999899.94% Upside
 · ·
SCYX
SCYNEXIS
 Aug 15, 2022 BUY Strong Buy
+215.8% avg upside
10 analysts
 — -41.0% ·
VERU
Veru
 Aug 11, 2022 BUY Strong Buy
+753.5% avg upside
11 analysts
$31.00
1191.59% Upside
 · ·
OTLK
Outlook Therapeutics
 Aug 11, 2022 BUY Buy
+1493.7% avg upside
11 analysts
$6.00
941.16% Upside
 · ·
ARCT
Arcturus Therapeutics
 Aug 10, 2022 BUY Buy
+142.7% avg upside
36 analysts
$74.00
482.73% Upside
 +3.4% ·
VXRT
Vaxart
 Aug 08, 2022 BUY Strong Buy
+1652.7% avg upside
8 analysts
$7.00
1525.10% Upside
 -85.3% ·
BCDA
BioCardia
 Aug 01, 2022 BUY Strong Buy
+1427.0% avg upside
5 analysts
 — · ·
NCEL
NewcelX
 Jun 02, 2022 BUY Strong Buy
+479.1% avg upside
4 analysts
$12.00
302.77% Upside
 · ·
LSTA
Lisata Therapeutics
 May 24, 2022 BUY Buy
+1134.1% avg upside
11 analysts
 — -57.1% ·
BGMS
Bio Green Med Solution
 May 13, 2022 BUY Strong Buy
+1377.9% avg upside
7 analysts
$22.00
2367.73% Upside
 · ·
TSE:MDNA
Medicenna Therapeutics Corp
 May 02, 2022 BUY Strong Buy
+1020.3% avg upside
9 analysts
$14.00
3118.40% Upside
 +58.7% ·
IMNN
Imunon
 Apr 05, 2022 BUY Strong Buy
+1283.3% avg upside
11 analysts
$45.00
4185.78% Upside
 · ·
DRMA
Dermata Therapeutics
 Sep 28, 2021 BUY Strong Buy
+229.9% avg upside
2 analysts
$2.00
110.17% Upside
 · ·
ARMP
Armata Pharmaceuticals
 Aug 17, 2021 BUY Strong Buy
+303.8% avg upside
4 analysts
$7.00
95.59% Upside
 +5.1% ·
HEPA
Hepion Pharmaceuticals
 Mar 23, 2021 BUY Strong Buy
+40877.8% avg upside
9 analysts
$6.00
4900.02% Upside
 · ·
CNSP
CNS Pharmaceuticals
 Feb 02, 2021 BUY Strong Buy
+422.5% avg upside
5 analysts
$10.00
85.18% Upside
 · ·
SCPX
Scorpius Holdings
 Dec 16, 2020 BUY Strong Buy
+9156150.0% avg upside
11 analysts
$35.00
17499900.00% Upside
 · ·
CLRB
Cellectar Biosciences
 Feb 20, 2020 BUY Strong Buy
+5054.3% avg upside
8 analysts
$6.00
316.60% Upside
 · ·
TARA
Protara Therapeutics
 Mar 28, 2019 HOLD Strong Buy
+1763.0% avg upside
21 analysts
 — -25.7% ·
OCGN
Ocugen
 Dec 24, 2018 HOLD Strong Buy
+896.8% avg upside
17 analysts
 — -77.4% ·
CRBP
Corbus Pharmaceuticals
 Oct 22, 2018 BUY Strong Buy
+583.1% avg upside
20 analysts
$25.00
383.46% Upside
 · ·
TNXP
Tonix Pharma
 Aug 30, 2018 HOLD Strong Buy
+321.4% avg upside
8 analysts
 — · ·
TXMD
TherapeuticsMD
 Aug 04, 2017 BUY Buy
+211.8% avg upside
8 analysts
 — · ·
BCRX
BioCryst
 May 26, 2017 BUY Strong Buy
+118.3% avg upside
24 analysts
 — -42.5% ·
AVXL
Anavex Life Sciences
 May 22, 2017 BUY Strong Buy
+1494.6% avg upside
9 analysts
 — -38.6% ·
XBIT
XBiotech
 May 16, 2017 HOLD Buy
+514.3% avg upside
2 analysts
$10.00
342.53% Upside
 +1.7% ·
HRTX
Heron Therapeutics
 May 10, 2017 BUY Strong Buy
+7013.9% avg upside
21 analysts
 — · ·
SLS
SELLAS Life Sciences Group
 Jun 29, 2016 HOLD Strong Buy
+460.1% avg upside
16 analysts
$0.40
96.58% Downside
 · ·
REGN
Regeneron
 Feb 25, 2016 BUY Strong Buy
+5.0% avg upside
59 analysts
$480.00
37.43% Downside
 -17.8% ·
GILD
Gilead Sciences
 Apr 06, 2015 BUY Strong Buy
-20.2% avg upside
66 analysts
$120.00
20.11% Downside
 -29.1% ·
🔒 44 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Kumaraguru Raja — Frequently Asked Questions
How accurate are Kumaraguru Raja's stock ratings?
Based on the calls 13Foresight could measure, about 32% of Kumaraguru's ratings were profitable over a one-year hold, with an average return of -1.1% per rating, or -14.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Kumaraguru ranked on 13Foresight?
Kumaraguru Raja is currently ranked #3191 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kumaraguru cover?
Kumaraguru most recently has ratings on BMEA, EDSA, ERNA, IRD, MDCX, NBP, INTS, ADIL, HURA, MNPR, IRLA, PALI and 37 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.